Physician profile
Catherine M Wang
NPI 1336219468
$482.79
in general payments reported to CMS, 2019-2025
10 companies · $20.42 in 2025
The $20.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $176 · 2024: $37.10 · 2025: $20.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.08 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.08 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $194.22 | 2019-2024 | |
| Focal Therapeutics, INC. | $92.16 | 2019 | |
| Lilly USA, LLC | $40.08 | 2024-2025 | Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.46 | 2019-2020 | |
| Therapeuticsmd, INC. | $22.06 | 2019 | |
| Glaxosmithkline, LLC. | $21.86 | 2019 | |
| Astellas Pharma US INC | $18.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.